167263-16-3

Basic information

• Product Name: 1-Piperidinecarboxylic acid, 4-[(dimethylamino)carbonyl]-4-phenyl-, 1,1-dimethylethyl ester
• CAS NO: 167263-16-3
• Molecular Formula: C19H28N2O3
• Molecular Weight: 332.443
• Mol File: 167263-16-3.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 1-Piperidinecarboxylic acid, 4-[(dimethylamino)carbonyl]-4-phenyl-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperidinecarboxylic acid, 4-[(dimethylamino)carbonyl]-4-phenyl-, 1,1-dimethylethyl ester(167263-16-3)
• EPA Substance Registry System: 1-Piperidinecarboxylic acid, 4-[(dimethylamino)carbonyl]-4-phenyl-, 1,1-dimethylethyl ester(167263-16-3)

Safety Data

• Hazardous Substances Data: 167263-16-3(Hazardous Substances Data)

Upstream product

• 167262-68-2 N-(t-butyloxycarbonyl)-4-phenylpiperidine-4-carboxylic acid 
• 124-40-3 dimethyl amine 

Downstream Products

• 2525-32-8 4-(N,N-dimethylaminocarbonyl)-4-phenylpiperidine 
• 83763-24-0 4-phenyl-piperidine-4-carboxylic acid dimethyl-amide hydrochloride 

Relevant articles and documents

Design, synthesis and evaluation of a novel cyclohexanamine class of neuropeptide Y Y1 receptor antagonists

A novel series of cyclohexanamine derivatives was designed and synthesized as potent and selective human neuropeptide Y Y1 receptor antagonists. Modification of high-throughput screening hit compound 1 resulted in the identification of compound 3i, which displays potent Y1 activity and good selectivity towards hERG K+ channel and serotonin transporter.

4,4-Disubstitued piperidines, and methods of use thereof

One aspect of the present invention relates to heterocyclic compounds. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian cellular receptors, including dopamine transporters. The comp

SUBSTITUTED PYRROLIDIN-3-YL-ALKYL-PIPERIDINES

The present invention relates to substituted pyrrolidinyl-3-yl-alkyl-piperidines, their stereoisomers, and pharmaceutically acceptable salts thereof and processes for preparation of the same. The compounds of the present invention are useful in their pharmacological activities such as tachykinin antagonism, especially substance P and neurokinin A antagonism, and the like. Compounds having the property of tachykinin antagonism are indicated for conditions associated with neurogenic inflammation and other diseases described herein.